Evidence map›Paper›PMID 40613498›Full record

ArticleFuture science OA2025

Hydrophobin-Fused SARS-CoV-2 RBD production in

Daniel Freire Lima, Cícero Matheus Lima Amaral, Arnaldo Solheiro Bezerra, Amauri Barbosa da Silva Junior, Yago Kayan de Souza Lima, Bruno Bezerra da Silva, Natalia do Vale Canabrava, Eridan Orlando Pereira Tramontina Florean, Reinaldo Barreto Oriá, Maria Izabel Florindo Guedes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel Freire LimaLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.ORCID 0000-0002-2635-8997
Cícero Matheus Lima AmaralLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Arnaldo Solheiro BezerraLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Amauri Barbosa da Silva JuniorLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Yago Kayan de Souza LimaLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Bruno Bezerra da SilvaLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Natalia do Vale CanabravaLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Eridan Orlando Pereira Tramontina FloreanLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.
Reinaldo Barreto OriáDepartment of Morphology and Institute of Biomedicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Maria Izabel Florindo GuedesLaboratory of Biotechnology and Molecular Biology, State University of Ceará, Fortaleza, Ceará, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe global health crisis underscores the need for accessible and cost-effective biomedical solutions, especially in resource-limited settings. Plant-based transient expression systems provide a viable method for producing recombinant proteins, such as the SARS-CoV-2 receptor-binding domain (RBD), for diagnostic applications. The addition of hydrophobin enhances protein purification efficiency and cost-effectiveness.

methodsThe study produced recombinant SARS-CoV-2 RBD fused to hydrophobin I (RBD-S-SCV2-HFBI) in

resultsThe RBD-S-SCV2-HFBI protein was successfully expressed in

conclusionThe study validates the feasibility of using RBD-S-SCV2-HFBI for diagnostic applications. Plant-based systems offer a rapid and cost-effective platform for producing high-quality recombinant proteins, providing scalable solutions to global health emergencies, particularly in resource-limited contexts.

Indexed as

COVID-19 pandemicRBD productionrecombinant proteinSARS-CoV-2transient expression

Identifiers

PMID40613498
PMCPMC12233689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.